Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.

British Journal of Clinical Pharmacology
Chloe TesmoingtThomas Papo

Abstract

To report a severe adverse event related to enzyme replacement therapy with agalsidase in an hemizygous male patient treated for Fabry disease. Retrospective analysis of clinical, radiological and biochemical data in a patient who suffered adverse events related to both agalsidase alfa and agalsidase beta treatments. A hemizygous male patient was first treated for Fabry disease with agalsidase alfa. After more than 1 year of therapy, infusion-related symptoms necessitated systemic steroids and antihistaminic therapy. Decline in kidney function prompted a switch for agalsidase beta. Anaphylactoid shock occurred after the second infusion. No serum IgE antibodies were disclosed. Skin-test reactivity to agalsidase beta was negative. Following a published rechallenge infusion protocol, agalsidase beta was reintroduced, leading to a second anaphylactoid shock episode. Enzyme replacement therapy was stopped and the patient was treated with symptomatic therapy only. This case was referred to the pharmacovigilance department. The negativity of immunological tests (specific anti-agalsidase IgE antibodies and skin tests) does not rule out the risk of repeated anaphylactoid shock following agalsidase infusion.

References

Nov 1, 1988·The Journal of Allergy and Clinical Immunology·D A Moneret-VautrinJ P Nicolas
May 1, 1982·Neurology·W J CableR D Adams
Jun 21, 2001·JAMA : the Journal of the American Medical Association·R SchiffmannR O Brady
Jul 7, 2001·The New England Journal of Medicine·C M EngUNKNOWN International Collaborative Fabry Disease Study Group
Jan 13, 2004·Proceedings of the National Academy of Sciences of the United States of America·E KakkisM Passage
Sep 15, 2004·Clinical Chemistry·Maria FullerPeter J Meikle
Oct 2, 2004·Kidney International·Gabor E LinthorstJohannes M F G Aerts
Jun 15, 2005·Clinical Genetics·Dominique P GermainCeline Mutschler
Oct 6, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Raphael SchiffmannRoscoe O Brady
Dec 21, 2006·Annals of Internal Medicine·Maryam BanikazemiUNKNOWN Fabry Disease Clinical Trial Study Group
Apr 6, 2007·Journal of the American Society of Nephrology : JASN·Dominique P GermainNathalie Guffon
Nov 27, 2007·Molecular Genetics and Metabolism·William R WilcoxUNKNOWN Fabry Registry
Dec 20, 2007·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Henriette MersebachUlla Feldt-Rasmussen
Feb 26, 2008·Journal of Neurology·Alessandro P BurlinaOlivier Lidove
Apr 22, 2008·Molecular Genetics and Metabolism·Anouk C VedderCarla E M Hollak
May 23, 2008·Genetics in Medicine : Official Journal of the American College of Medical Genetics·David BodensteinerDominique P Germain

❮ Previous
Next ❯

Citations

Jan 5, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Elfrida R BenjaminKenneth J Valenzano
May 27, 2011·Assay and Drug Development Technologies·Kenneth J ValenzanoElfrida R Benjamin
Oct 22, 2010·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Olivier LidoveAtul Mehta
Dec 18, 2013·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Neetu TalrejaRichard F Lockey
Apr 29, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Su XuRichie Khanna
Jun 7, 2019·Current Opinion in Allergy and Clinical Immunology·Anna Sala-CunillVictoria Cardona
Aug 19, 2020·International Journal of Molecular Sciences·Sanne J van der VeenMirjam Langeveld
Mar 23, 2018·JCI Insight·James J MillerNancy M Dahms
Apr 30, 2021·Néphrologie & thérapeutique·Frédéric BarbeyOlivier Dormond

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.